陕西中医2018，Vol.39Issue(11)：1508-1510,3.DOI:10.3969/j.issn.1000-7369.2018.11.005
八珍汤治疗恶性肿瘤化疗后白细胞减少症临床研究
Clinical safety and efficacy of Bazhen decoction on chemotherapy-induced myelosuppression and leucopenia for patients with malignant tumor
摘要
Abstract
Objective :To evaluate clinical efficacy and safety of Bazhen decoction on chemotherapy-induced myelosuppression and leucopenia for patients with malignant tumor .Methods :Sixty cases with leukopenia after ma-lignant tumor chemotherapy were randomly divided into treatment group and control group ,30 cases in each group . Patients in control group were treated with Diyu Shengbai tablets ,100 mg(po) ,3 timesa day .Patients in treatment group were treated with Bazhen decoction ,200ml once ,twice daily .Two weeks for a course ,and both groups were treated for 3 courses .The leukocyte count before and after treatmentand the clinical effect after treatment of two groups were compared ,alsothe security was evaluated .Results :The total effective rate was 86 .67% in treatment group ,much higher than 73 .33% in control group(P＜0 .05).The leukocyte count apparently rised after treatment inboth groups (P＜0 .05) ,while in treatment group ,it rised to muchhigher than that in control group (P＜0 .05). No obvious adverse reactions of the two groups occourred .Conclusion :Compared to Diyu Shengbai tablets ,Bazhen decoction has better clinical efficacy on thetreatment of leukopenia after malignant tumor chemotherapy ,simultane-ously ,there are no adverse reaction soccourred in both group .关键词
肿瘤/中西医结合疗法/@白细胞减少症/八珍汤/治疗应用Key words
Neoplasms/integrated Chinese traditional and western medicine therapy/@Leukopenia/Ba Zhen Tang /therapeutic uses分类
医药卫生引用本文复制引用
魏海梁,李京涛,闫曙光,肖刚,李婵,司明明,郭辉..八珍汤治疗恶性肿瘤化疗后白细胞减少症临床研究[J].陕西中医,2018,39(11):1508-1510,3.基金项目
陕西省中医药管理局课题(JCMS042)陕西省科技厅社会发展攻关项目( 2017SF-338 （JCMS042）
2018SF-284)咸阳市科学技术研究计划项目( 2017k02-84) （ 2017k02-84）
